Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Regeneron Pharmaceuticals picked up a meaningful endorsement from UBS on October 15. The upgrade arrived as short sellers have been quietly pulling back, and with Q3 earnings just 15 days away.
UBS analyst Trung Huynh lifted REGN to Buy from Neutral, raising the price target to $978 from $660. That is a 48% jump in the target. It implies 26% upside from the $778 close. The upgrade stands out against the recent run of Street moves: while JP Morgan, Jefferies, Truist and Argus have all lifted targets over the past two weeks, UBS is the first to make a formal rating change upward. The consensus mean target now sits at $863.93. UBS is well above that.
The bull case rests on Dupixent's durability, the Eylea HD pre-filled syringe opportunity, and pipeline catalysts including the cemdisiran gMG PDUFA in Q4 2026. Factor scores corroborate the constructive analyst trend. The 12-month forward EPS year-on-year increase ranks at the 97th percentile. The analyst recommendation differential sits at the 92nd percentile. EPS momentum over 30 and 90 days ranks at the 84th and 88th percentiles respectively.
The bear case has not gone away. Biosimilar pressure on original Eylea remains a structural headwind. The fianlimab Phase III miss in first-line metastatic melanoma (hazard ratio 0.845, p=0.0627) is a live reminder that the oncology pipeline carries real clinical risk. Morgan Stanley's Equal-Weight and $779 target, essentially at current prices, reflects that caution.
Short interest has fallen 14.4% over the past week to 2.14 million shares, or 2.1% of free float. That is near a three-month low. At 2.1% of float, the short position is not large enough to be a primary driver of price action. The borrow market confirms the same picture. Availability remains exceptionally loose, with 97.6 million shares available to lend against 2.1 million currently borrowed. Cost to borrow is 0.44%, up 237% week-on-week, but that is a move from a near-zero base. At 0.44%, borrowing REGN is still cheap. The uptick in CTB is a minor technical footnote, not a signal of conviction building on the short side.
The October 30 earnings print is the next hard catalyst. The last two prints moved the stock 9.7% and 6.2% on the day. Medicaid reimbursements for Regeneron's drugs fell 26% year-on-year in Q1 2026 and have declined for three consecutive quarters, per CMS data, a headwind worth watching against Dupixent growth figures in the Q3 report.
ORTEX also flags a binary index decision at the December 2026 Quarterly Review: REGN is a candidate for a share count increase in the CRSP US Mid index and simultaneously for deletion from the CRSP US Mega index, both at 45% probability. The deciding price for the Mega exit is $745.89. The stock sits 4.2% above that line today.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
